论坛简介
论坛简介

“炎症免疫反应软调节”学术论坛

Academic forum on Soft regulation of inflammatory immune responses

  

  

2015年,安徽医科大学临床药理研究所魏伟教授根据多年研究实践,首次提出了新的学术概念---炎症免疫反应软调节,发表在《中国药理学通报》(魏伟.炎症免疫反应软调节.中国药理学通报, 2016;32(3) 297-303)。近两年来,魏伟教授在国内国际多个会议上应邀作“炎症免疫反应软调节”的学术报告,得到同行的高度关注。

炎症免疫反应(inflammatory immune responses, IIR)是机体炎症免疫相关细胞依据内外环境变化所表现出的适度或异常的系统反应;参与IIR的炎症免疫细胞及细胞因子/受体信号转导是多个系统疾病的病理基础;目前临床上使用的影响IIR药物存在许多安全性问题。

炎症免疫反应软调节(soft regulation of inflammatory immune responses, SRIIR)是指药物对细胞功能、基因和蛋白表达或活性不是完全抑制,而是选择性调节异常活性至生理水平,以恢复细胞和整体的动态平衡,发挥治疗作用并尽量减少不良反应。SRIIR是创新药物研发的重要方向。

为了加强“炎症免疫反应软调节”的学术交流,吸引和碰撞不同见解,推动领域基础与应用研究,我们将于20176月开始举办“炎症免疫反应软调节”论坛系列学术活动,包括邀请专家演讲、专题研讨、区域会议、国内和国际会议、成果交流等形式。

  

  

  

安徽医科大学临床药理研究所

抗炎免疫药物教育部重点实验室

安徽省抗炎免疫药物协同创新中心

  

  

  

In 2015, Prof. Wei Wei from Institute of Clinical Pharmacology, Anhui Medical University puts forward a new academic concept - soft regulation of inflammatory immune responses for the first time according to many years research practices. The new academic concept was published in the journal of “Chinese Pharmacological Bulletin” (Wei Wei. Soft regulation of inflammatory immune responses. Chinese Pharmacological Bulletin, 2016; 32 (3), 297-303).In the past two years, Prof. Wei was invited to give academic reports of “Soft regulation of inflammatory immune responses” in some domestic and international conferences. These reports got much attention from researchers.

Inflammatory immune responses ( IIR) is defined an adapted or abnormal system responses of inflammatory immune related cells in responding to the internal and external environment changes of body. Inflammatory immune cells and cytokines /receptor signal transduction involved in IIR are the pathological basis of multiple system diseases. Many security problems of the drugs affecting IIR used in clinic exist.

Soft regulation of inflammatory immune responses (SRIIR) refers to drugs that do not completely suppress cell function, gene and protein expression or activity, but regulate selectively abnormal activity to physiological level, restore dynamic balance, and play a role in treatment and reducing adverse reactions. SRIIR is one of the important direction of innovative drug development.

In order to strengthen the academic exchanges for “Soft regulation of inflammatory immune responses”, attract the different ideas, and promote the basic and applied research of “Soft regulation of inflammatory immune response ”, we will hold series of academic activities for “Soft  regulation of inflammatory immune response” from June 2017, including expert lectures, disscussions, regional meetings, domestic and international meetings, achivements communication, and so on.

  

  

  

Institute of Clinical Pharmacology, Anhui Medical University,

Key Laboratory of Anti-inflammatory and Immune Medicine, Education Ministry of China,

Anhui Collaborative Innovation Center of Anti-inflammatory  and Immune Medicine .